Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History
Open Access
- 2 August 2023
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (5) , 2703-2712
Abstract
Introduction The aim of this study was to investigate the safety and efficacy of a single injection of intravitreal faricimab (IVF) in patients with neovascular age-related macular degeneration (nAMD) who had a prior treatment history. Methods A retrospective analysis was conducted on a consecutive cohort of 80 eyes of 75 patients with nAMD who had a prior history of treatment with an injection of anti-vascular endothelial growth factor. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and central choroidal thickness (CCT) were compared before the initial IVF injection and after a treatment interval matching the previous duration. Results Central choroidal thickness decreased significantly following the IVF injection, but there was no significant change in BCVA or CST. Mean (± standard deviation) BCVA changed from 0.34 ± 0.37 to 0.36 ± 0.40 (P = 0.29), CST changed from 242 ± 72 to 242 ± 82 µm (P = 0.99), and CCT changed from 189 ± 98 to 179 ± 97 µm (P < 0.0001). When the changes were evaluated according to the previous anti-VEGF agent administered, CCT was found to be significantly decreased by 8.7 ± 2.5 µm (P < 0.0001) in eyes previously treated with brolucizumab and by 13.1 ± 3.6 µm (P < 0.0001) in eyes previously treated with aflibercept. No adverse events were observed during the study period. Conclusion Intravitreal faricimab injection is a safe and effective treatment for nAMD in terms of short-term outcomes. Further long-term study is necessary.Keywords
This publication has 27 references indexed in Scilit:
- Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Therapeutic targeting of the angiopoietin–TIE pathwayNature Reviews Drug Discovery, 2017
- Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2017
- Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular DegenerationOphthalmology, 2016
- One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal VasculopathyOphthalmology, 2015
- Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2015
- Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese PatientsAmerican Journal of Ophthalmology, 2007
- Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study1 1The authors have no proprietary interest in the products or devices mentioned herein.Ophthalmology, 2002
- Five-year incidence of age-related maculopathy lesionsOphthalmology, 2002